

PATIENT NAME : SHEETAL SHARAD MARATHE	R	REF. DOCTOR : S	SELF	
	ACCESSION NO : 0002V	VC050221	AGE/SEX : 36 Yea	ars Female
	PATIENT ID : SHEEF2	2209862	DRAWN :25/03/	/2023 08:44:47
AWING 1705RIZVI CEDER MALAD E 400097	CLIENT PATIENT ID:		RECEIVED : 25/03	/2023 08:46:36
400037	ABHA NO :		REPORTED :27/03/	/2023 11:04:30
Test Report Status <u>Final</u>	Results	Biological	Reference Interv	val Units
MEDI WHEEL FULL BODY HEALTH CHECKUP BEI	<u>OW 40FEMALE</u>			
KRAY-CHEST				
MPRESSION	NO ABNORMALITY DET	ECTED		
IMT OR ECHO				
IMT OR ECHO	2D ECHO IMPRESSION GOOD LV SYSTOLIC FU LVEF 60% ALL VALVES STRUCTUF NO EVIDENCE OF PE/C	INCTION AT REST RALLY NORMAL.		
ECG				
ECG	NON SPECIFIC T INVER	RSION III IN AVF		
MEDICAL HISTORY				
RELEVANT PRESENT HISTORY	FUNGAL INFECTION SI	NCE 3 WEEKS.		
RELEVANT PAST HISTORY	COVID 19 IN 2022. JAUNDICE IN 12 YRS C FRACTURE IN RIGHT H		DOD.	
RELEVANT PERSONAL HISTORY	NOT SIGNIFICANT			
MENSTRUAL HISTORY (FOR FEMALES)	DELAYED			
_MP (FOR FEMALES)	25/2/2023			
OBSTETRIC HISTORY (FOR FEMALES)	NOT SIGNIFICANT			
RELEVANT FAMILY HISTORY	FATHER / MOTHER : DI	IABETES / HYPER	TENSION.	
HISTORY OF MEDICATIONS	NOT SIGNIFICANT			
ANTHROPOMETRIC DATA & BMI				
HEIGHT IN METERS	1.64			mts
WEIGHT IN KGS.	105.2			Kgs
BMI	39	Below 18. 18.5 - 24. 25.0 - 29.	ight Status as fol 5: Underweight 9: Normal 9: Overweight Above: Obese	llo \vg /sqmts
GENERAL EXAMINATION				
MENTAL / EMOTIONAL STATE	NORMAL			
PHYSICAL ATTITUDE	NORMAL			
GENERAL APPEARANCE / NUTRITIONAL STATUS	OBESE			
BUILT / SKELETAL FRAMEWORK	AVERAGE			
Herkel				Dana 1 06 22
				Page 1 Of 22

Dr. J N Shukla ,MBBS, AFIH **Consultant Physician**










PATIENT NAME : SHEETAL SHARAD MARATHE	REF. D	OCTOR : S	ELF	
	ACCESSION NO : 0002WC050	221	AGE/SEX	:36 Years Female
	PATIENT ID : SHEEF220986	52	DRAWN	:25/03/2023 08:44:42
AWING 1705RIZVI CEDER MALAD E 400097	CLIENT PATIENT ID:		RECEIVED	:25/03/2023 08:46:36
400097	ABHA NO :		REPORTED	:27/03/2023 11:04:30
Test Report Status <u>Final</u>	Results E	iological F	leferenc	e Interval Units
FACIAL APPEARANCE	NORMAL			
SKIN	PALE SKIN			
UPPER LIMB	NORMAL			
LOWER LIMB	NORMAL			
NECK	NORMAL			
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDER			
THYROID GLAND	NOT ENLARGED			
CAROTID PULSATION	NORMAL			
TEMPERATURE	NORMAL			
PULSE	76/MIN.REGULAR, ALL PERIP BRUIT	HERAL PUL	SES WELL	FELT, NO CAROTID
RESPIRATORY RATE	NORMAL			
CARDIOVASCULAR SYSTEM				
BP	124/80 MM HG (SUPINE)			mm/Hg
PERICARDIUM	NORMAL			
APEX BEAT	NORMAL			
HEART SOUNDS	NORMAL			
MURMURS	ABSENT			
RESPIRATORY SYSTEM				
SIZE AND SHAPE OF CHEST	NORMAL			
MOVEMENTS OF CHEST	SYMMETRICAL			
BREATH SOUNDS INTENSITY	NORMAL			
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)			
ADDED SOUNDS	ABSENT			
PER ABDOMEN				
APPEARANCE	NORMAL			
VENOUS PROMINENCE	ABSENT			
LIVER	NOT PALPABLE			
SPLEEN	NOT PALPABLE			
HERNIA	ABSENT			
CENTRAL NERVOUS SYSTEM				
HIGHER FUNCTIONS	NORMAL			



Dr. J N Shukla ,MBBS, AFIH Consultant Physician



Page 2 Of 22









PATIENT NAME : SHEETAL SHARAD MARATHE	HE REF. DOCTOR : SELF			
	ACCESSION NO : 0002WC050221	AGE/SEX : 36 Years Female		
	PATIENT ID : SHEEF2209862	DRAWN :25/03/2023 08:44:47		
AWING 1705RIZVI CEDER MALAD E 400097	CLIENT PATIENT ID:	RECEIVED : 25/03/2023 08:46:36		
	ABHA NO :	REPORTED :27/03/2023 11:04:30		
Test Report Status <u>Final</u>	Results Biologica	Reference Interval Units		
CRANIAL NERVES	NORMAL			
CEREBELLAR FUNCTIONS	NORMAL			
SENSORY SYSTEM	NORMAL			
MOTOR SYSTEM	NORMAL			
REFLEXES	NORMAL			
MUSCULOSKELETAL SYSTEM				
SPINE	NORMAL			
JOINTS	NORMAL			
BASIC EYE EXAMINATION				
CONJUNCTIVA	NORMAL			
EYELIDS	NORMAL			
EYE MOVEMENTS	NORMAL			
CORNEA	NORMAL			
DISTANT VISION RIGHT EYE WITH GLASSES	WITH GLASSES NORMAL (6/6)			
DISTANT VISION LEFT EYE WITH GLASSES	WITH GLASSES NORMAL (6/6)			
NEAR VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT (N6)			
NEAR VISION LEFT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT (N6)			
COLOUR VISION	NORMAL (17/17)			
BASIC ENT EXAMINATION				
EXTERNAL EAR CANAL	NORMAL			
TYMPANIC MEMBRANE	NORMAL			
NOSE	NO ABNORMALITY DETECTED			
SINUSES	CLEAR			
THROAT	NO ABNORMALITY DETECTED			
TONSILS	NOT ENLARGED			
BASIC DENTAL EXAMINATION				
TEETH	NORMAL			
GUMS	HEALTHY			
SUMMARY				
RELEVANT HISTORY	NOT SIGNIFICANT			
RELEVANT GP EXAMINATION FINDINGS	NOT SIGNIFICANT			
RELEVANT LAB INVESTIGATIONS	WITHIN NORMAL LIMITS			



Dr. J N Shukla ,MBBS, AFIH Consultant Physician

Page 3 Of 22









PATIENT NAME : SHEETAL SHARAD MARATHE	REF. DOCTOR :	SELF
	ACCESSION NO : 0002WC050221	AGE/SEX : 36 Years Female
	PATIENT ID : SHEEF2209862	DRAWN :25/03/2023 08:44:47
AWING 1705RIZVI CEDER MALAD E 400097	CLIENT PATIENT ID:	RECEIVED : 25/03/2023 08:46:36
400097	ABHA NO :	REPORTED :27/03/2023 11:04:30
Test Report Status <u>Final</u>	Results Biologica	I Reference Interval Units

RELEVANT NON PATHOLOGY DIAGNOSTICS **REMARKS / RECOMMENDATIONS**

USG-NO ABNORMALITIES DETECTED ADV FOR OVERWEIGHT LOW CALORIE DIET REGULAR PHYSICIAL EXERCISE ADV- VITAMIN D AND VITAMIN B12 TEST FOLLOW UP WITH PHYSICIAN



Dr. J N Shukla , MBBS, AFIH **Consultant Physician**



Page 4 Of 22

Vie<u>w</u> Details





PATIENT NAME : SHEETAL SHARAD MARATHE	REF. DOCTOR :	SELF
	ACCESSION NO : 0002WC050221	AGE/SEX : 36 Years Female
	PATIENT ID : SHEEF2209862	DRAWN :25/03/2023 08:44:47
AWING 1705RIZVI CEDER MALAD E 400097	CLIENT PATIENT ID:	RECEIVED : 25/03/2023 08:46:36
400097	ABHA NO :	REPORTED :27/03/2023 11:04:30
Test Report Status <u>Final</u>	Results	Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN

NO ABNORMALITIES DETECTED

Interpretation(s) MEDICAL



Dr. J N Shukla ,MBBS, AFIH Consultant Physician



Page 5 Of 22

View Report

PERFORMED AT : SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956







PATIENT NAME : SHEETAL SHARAD MARATHE REF. DOCTOR : SELF ACCESSION NO : 0002WC050221 AGE/SEX :36 Years Female :25/03/2023 08:44:47 PATIENT ID : SHEEF2209862 DRAWN AWING 1705RIZVI CEDER MALAD E CLIENT PATIENT ID: RECEIVED : 25/03/2023 08:46:36 400097 REPORTED :27/03/2023 11:04:30 ABHA NO :

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units

HAEMATOLOGY - CBC					
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE					
BLOOD COUNTS, EDTA WHOLE BLOOD					
HEMOGLOBIN (HB) METHOD : PHOTOMETRIC MEASUREMENT	12.2	12.0 - 15.0	g/dL		
RED BLOOD CELL (RBC) COUNT METHOD : COULTER PRINCIPLE	4.61	3.8 - 4.8	mil/µL		
WHITE BLOOD CELL (WBC) COUNT METHOD : COULTER PRINCIPLE	6.70	4.0 - 10.0	thou/µL		
PLATELET COUNT METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY	222	150 - 410	thou/µL		
RBC AND PLATELET INDICES					
HEMATOCRIT (PCV) METHOD : CALCULATED PARAMETER	37.0	36.0 - 46.0	%		
MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	80.3 Low	83.0 - 101.0	fL		
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER	26.5 Low	27.0 - 32.0	pg		
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER	33.0	31.5 - 34.5	g/dL		
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	14.2 High	11.6 - 14.0	%		
MENTZER INDEX	17.4				
MEAN PLATELET VOLUME (MPV) METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM	8.4	6.8 - 10.9	fL		
WBC DIFFERENTIAL COUNT					
NEUTROPHILS METHOD : VCSN TECHNOLOGY/ MICROSCOPY	71	40 - 80	%		
LYMPHOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY	19 Low	20 - 40	%		
MONOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY	7	2.0 - 10.0	%		
EOSINOPHILS METHOD : VCSN TECHNOLOGY/ MICROSCOPY	3	1.0 - 6.0	%		

Dr. Reena Mittal, MD Senior Consultant Hematopathologist



Dr. Sushant Chikane Consultant Pathologist Page 6 Of 22









REF. DOCTOR : SELF PATIENT NAME : SHEETAL SHARAD MARATHE ACCESSION NO : 0002WC050221 AGE/SEX :36 Years Female :25/03/2023 08:44:47 PATIENT ID : SHEEF2209862 DRAWN AWING 1705RIZVI CEDER MALAD E CLIENT PATIENT ID: RECEIVED : 25/03/2023 08:46:36 400097 ABHA NO REPORTED :27/03/2023 11:04:30 : Test Report Status Results **Biological Reference Interval** Units <u>Final</u> 0 0 - 1 % BASOPHILS METHOD : VCSN TECHNOLOGY/ MICROSCOPY thou/µL ABSOLUTE NEUTROPHIL COUNT 4.80 2.0 - 7.0 METHOD : CALCULATED PARAMETER ABSOLUTE LYMPHOCYTE COUNT 1.20 1.0 - 3.0 thou/µL

		210 010	71
METHOD : CALCULATED PARAMETER			
ABSOLUTE MONOCYTE COUNT	0.47	0.2 - 1.0	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE EOSINOPHIL COUNT	0.20	0.02 - 0.50	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10	thou/µL
METHOD : CALCULATED PARAMETER			
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	4.0		

METHOD : CALCULATED

Interpretation(s) BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Reena Mittal, MD Senior Consultant Hematopathologist

Dr. Sushant Chikane Consultant Pathologist



View Repor

Page 7 Of 22





0 - 20



PATIENT NAME : SHEETAL SHARAD MARATHE	REF. DOCTOR : SELF			
	ACCESSION NO : 0002WC050221	AGE/SEX : 36 Years Female		
AWING 1705RIZVI CEDER MALAD E 400097	PATIENT ID : SHEEF2209862	DRAWN :25/03/2023 08:44:47		
	CLIENT PATIENT ID:	RECEIVED : 25/03/2023 08:46:36		
	ABHA NO :	REPORTED :27/03/2023 11:04:30		
Test Report Status <u>Final</u>	Results Biologi	cal Reference Interval Units		

HAEMATOLOGY
WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

16

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE

BLOOD

MEDI V

E.S.R

METHOD : AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)

mm at 1 hr

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr. Reena Mittal, MD Senior Consultant Hematopathologist

Dr. Sushant Chikane Consultant Pathologist



Vie<u>w Report</u>

Page 8 Of 22







PATIENT NAME : SHEETAL SHARAD MARATHE **REF. DOCTOR : SELF** ACCESSION NO : 0002WC050221 AGE/SEX :36 Years Female PATIENT ID DRAWN :25/03/2023 08:44:47 : SHEEF2209862 AWING 1705RIZVI CEDER MALAD E CLIENT PATIENT ID: RECEIVED : 25/03/2023 08:46:36 400097 ABHA NO REPORTED :27/03/2023 11:04:30 : Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

IMMUNOHAEMATOLOGY MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP A METHOD : HAEMAGGLUTINATION (AUTOMATED) POSITIVE RH TYPE

METHOD : HAEMAGGLUTINATION (AUTOMATED)

Interpretation(s) ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

Dr. Sushant Chikane **Consultant Pathologist**



Page 9 Of 22

View Repor








PATIENT NAME : SHEETAL SHARAD MARATHE	REF. DOCTOR :	SELF
	ACCESSION NO : 0002WC050221	AGE/SEX : 36 Years Female
	PATIENT ID : SHEEF2209862	DRAWN :25/03/2023 08:44:47
AWING 1705RIZVI CEDER MALAD E 400097	CLIENT PATIENT ID:	RECEIVED : 25/03/2023 08:46:36
400097	ABHA NO :	REPORTED :27/03/2023 11:04:30
	Besulte Bislesier	
Test Report Status <u>Final</u>	Results Biologica	al Reference Interval Units

	BIOCHEMISTRY		
MEDI WHEEL FULL BODY HEALTH CHECKUP E	BELOW 40FEMALE		
GLUCOSE FASTING, FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR)	88	Normal <100 Impaired fasting glucose:10 125 Diabetes mellitus: > = 126 more than 1 occassion) (ADA guidelines 2021)	
METHOD : SPECTROPHOTOMETRY HEXOKINASE		, <u>,</u> ,	
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA BLOOD	A WHOLE		
HBA1C	4.9	Non-diabetic Adult < 5.7 Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
METHOD : ION- EXCHANGE HPLC			
ESTIMATED AVERAGE GLUCOSE(EAG)	93.9	< 116	mg/dL
GLUCOSE, POST-PRANDIAL, PLASMA			
PPBS(POST PRANDIAL BLOOD SUGAR)	66	Normal <140 Impaired glucose tolerance:140 to 199 Diabetes mellitus : > = 200 (on more than 1 occassion) ADA guideline 2021	mg/dL
METHOD : SPECTROPHOTOMETRY HEXOKINASE			
LIPID PROFILE, SERUM			
CHOLESTEROL, TOTAL	156	Desirable : < 200 Borderline : 200 - 239 High : > / = 240	mg/dL
METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC -	CHOLETSEROL OXIDASE, ESTERASE	- ·	
TRIGLYCERIDES	52	Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500	mg/dL

METHOD : SPECTROPHOTOMETRY, ENZYMATIC ENDPOINT WITH GLYCEROL BLANK

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 10 Of 22



Vie<u>w</u> Details







PATIENT NAME : SHEETAL SHARAD MARATHE REF. DOCTOR : SELF ACCESSION NO : 0002WC050221 AGE/SEX :36 Years Female PATIENT ID DRAWN :25/03/2023 08:44:47 : SHEEF2209862 AWING 1705RIZVI CEDER MALAD E CLIENT PATIENT ID: RECEIVED : 25/03/2023 08:46:36 400097 ABHA NO REPORTED :27/03/2023 11:04:30 : Test Report Status Final Results

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
HDL CHOLESTEROL	42	At Risk: < 40 mg/dL Desirable: > or = 60
METHOD : SPECTROPHOTOMETRY, HOMOGENEOUS DIRECT	ENZYMATIC COLORIMETRIC	
CHOLESTEROL LDL	104 High	Optimal : < 100 mg/dL Near optimal/above optimal : 100-129 Borderline high : 130-159 High : 160-189 Very high : = 190
METHOD : CALCULATED PARAMETER		
NON HDL CHOLESTEROL	114	Desirable : < 130 mg/dL Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : $> / = 220$
METHOD : CALCULATED PARAMETER		
VERY LOW DENSITY LIPOPROTEIN METHOD : CALCULATED PARAMETER	10.0	< or = 30.0 mg/dL
CHOL/HDL RATIO	3.7	Low Risk : 3.3 - 4.4 Average Risk : 4.5 - 7.0 Moderate Risk : 7.1 - 11.0 High Risk : > 11.0
METHOD : CALCULATED PARAMETER		
LDL/HDL RATIO	2.8	Desirable/Low Risk : 0.5 - 3.0 Borderline/Moderate Risk : 3.1 - 6.0 High Risk : > 6.0
METHOD : CALCULATED PARAMETER		-

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for	ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India				
Risk Category					
Extreme risk group	A.CAD with > 1 feature of high risk group				
B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or =					
	50 mg/dl or polyvascular disease				
Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3.				
	Familial Homozygous Hypercholesterolemia				

8. wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist











MC-2010

	EETAL SH	ARAD MARATHE			REF. DOCTOR :	SELF		
			ACCESSI	ON NO : 0002	WC050221	AGE/SEX : 3	6 Years	Female
			PATIENT ID : SHEEF2209862		DRAWN :2	5/03/2023	08:44:47	
WING 1705RIZVI CEE	DER MALAD	E	CLIENT P	ATIENT ID:		RECEIVED : 2	5/03/2023	08:46:36
400097			АВНА NO) :		REPORTED :2		
est Report Status	<u>Final</u>		Resu	lts	Biological	Reference I	nterval U	Inits
		ajor ASCVD risk factor						
	Artery Calci	CKD stage 3B or 4. 4. ium - CAC >300 AU.						
		CVD risk factors						
Low Risk Major ASCVD (Ather		SCVD risk factors) Rick Fa	etors				
1. Age > or = 45 years					garette smoking or t	tobacco use		
2. Family history of pre				4. High blood				
5. Low HDL								
lewer treatment goals a	und statin in		sed on th	e risk categori				
Risk Group		Treatment Goals LDL-C (mg/dl)	Non H	IDL (mg/dl)	Consider Drug T LDL-C (mg/dl)	herapy Non-HDL (ma/dl)	
Extreme Risk Group Ca	ategory A	<50 (Optional goal		Optional goal	>OR = 50	>OR = 80	mg/m)	
Entreme rusk Group G	acegory 11	< OR = 30)	<or =<="" td=""><td></td><td>on ou</td><td>on ov</td><td></td><td></td></or>		on ou	on ov		
Extreme Risk Group Ca	ategory B	<or 30<="" =="" td=""><td><or =<="" td=""><td>60</td><td>> 30</td><td>>60</td><td></td><td></td></or></td></or>	<or =<="" td=""><td>60</td><td>> 30</td><td>>60</td><td></td><td></td></or>	60	> 30	>60		
Very High Risk		<50	<80		>OR= 50	>OR= 80		
High Risk Moderate Pisk		<70	<100		>OR=70	>OR=100 >OR=120		
Moderate Risk Low Risk		<100 <100	<130		>OR=100 >OR=130*	>OR=130 >OR=160		
ndia. Current Vascular P IVER FUNCTION PR BILIRUBIN, TOTAL		RUM	0.33		Upto 1.2		mg,	/dL
			0.02				-	
METHOD : SPECTROPHOTOM			0.19		< or = 0.	3	mg,	/dL
METHOD : SPECTROPHOTOM					< or = 0.	3	mg,	/dL
METHOD : SPECTROPHOTOM BILIRUBIN, DIRECT METHOD : SPECTROPHOTOM	1etry, jendras CT	SSIK & GROFF - DIAZOTIZA			< or = 0. 0.0 - 0.9	3	mg, mg,	
METHOD : SPECTROPHOTOM BILIRUBIN, DIRECT METHOD : SPECTROPHOTOM BILIRUBIN, INDIREC METHOD : CALCULATED PAR	1etry, jendras CT	SSIK & GROFF - DIAZOTIZA	ATION			3	-	/dL
METHOD : SPECTROPHOTOM BILIRUBIN, DIRECT METHOD : SPECTROPHOTOM BILIRUBIN, INDIREC METHOD : CALCULATED PAR	ietry, jendra: CT Rameter	SSIK & GROFF - DIAZOTIZA	0.14 6.1	RUM BLANK	0.0 - 0.9	3	mg,	/dL
METHOD : SPECTROPHOTOM BILIRUBIN, DIRECT METHOD : SPECTROPHOTOM BILIRUBIN, INDIREC METHOD : CALCULATED PAR FOTAL PROTEIN METHOD : SPECTROPHOTOM	1etry, jendras CT Rameter 1etry, colorii	SSIK & GROFF - DIAZOTIZA METRIC -BIURET, REAGENT	апол 0.14 6.1 вlank, se 3.7 Lo		0.0 - 0.9	-	mg,	/dL L
METHOD : SPECTROPHOTOM BILIRUBIN, DIRECT METHOD : SPECTROPHOTOM BILIRUBIN, INDIREC METHOD : CALCULATED PAR TOTAL PROTEIN METHOD : SPECTROPHOTOM ALBUMIN METHOD : SPECTROPHOTOM	IETRY, JENDRAS CT RAMETER IETRY, COLORIJ IETRY, BROMOC	SSIK & GROFF - DIAZOTIZA METRIC -BIURET, REAGENT	апол 0.14 6.1 вlank, se 3.7 Lo		0.0 - 0.9 6.0 - 8.0	-	mg, g/d	/dL L L
METHOD : SPECTROPHOTOM BILIRUBIN, DIRECT METHOD : SPECTROPHOTOM BILIRUBIN, INDIREC METHOD : CALCULATED PAR FOTAL PROTEIN METHOD : SPECTROPHOTOM ALBUMIN METHOD : SPECTROPHOTOM GLOBULIN METHOD : CALCULATED PAR	IETRY, JENDRAS CT RAMETER IETRY, COLORII IETRY, BROMOC RAMETER I RATIO	SSIK & GROFF - DIAZOTIZA METRIC -BIURET, REAGENT	6.1 BLANK, SE 3.7 LOV		0.0 - 0.9 6.0 - 8.0 3.97 - 4.9	-	mg, g/d g/d	/dL L L
METHOD : SPECTROPHOTOM BILIRUBIN, DIRECT METHOD : SPECTROPHOTOM BILIRUBIN, INDIREC METHOD : CALCULATED PAR FOTAL PROTEIN	ietry, jendra: CT Rameter	SSIK & GROFF - DIAZOTIZA	0.14 6.1	RUM BLANK	0.0 - 0.9	3	mg,	/dL
METHOD : SPECTROPHOTOM BILIRUBIN, DIRECT METHOD : SPECTROPHOTOM BILIRUBIN, INDIREC METHOD : CALCULATED PAR TOTAL PROTEIN METHOD : SPECTROPHOTOM ALBUMIN METHOD : CALCULATED PAR ALBUMIN/GLOBULIN	IETRY, JENDRAS CT RAMETER IETRY, COLORII IETRY, BROMOC RAMETER I RATIO RAMETER	SSIK & GROFF - DIAZOTIZA METRIC -BIURET, REAGENT CRESOL GREEN(BCG) - DYE	6.1 BLANK, SE 3.7 LOV BINDING 2.4		0.0 - 0.9 6.0 - 8.0 3.97 - 4.9 2.0 - 3.5	-	mg, g/d g/d	/dL L L TO
METHOD : SPECTROPHOTOM BILIRUBIN, DIRECT METHOD : SPECTROPHOTOM BILIRUBIN, INDIREC METHOD : CALCULATED PAR FOTAL PROTEIN METHOD : SPECTROPHOTOM ALBUMIN METHOD : SPECTROPHOTOM GLOBULIN METHOD : CALCULATED PAR ALBUMIN/GLOBULIN METHOD : CALCULATED PAR ASPARTATE AMINOT	IETRY, JENDRAS CT RAMETER IETRY, COLORII IETRY, BROMOC RAMETER I RATIO RAMETER TRANSFER	SSIK & GROFF - DIAZOTIZA METRIC -BIURET, REAGENT CRESOL GREEN(BCG) - DYE	6.1 BLANK, SE 3.7 LO BINDING 2.4 1.5 15	w	0.0 - 0.9 6.0 - 8.0 3.97 - 4.9 2.0 - 3.5 1.0 - 2.1	-	mg, g/d g/d RAT	/dL L L TO
METHOD : SPECTROPHOTOM BILIRUBIN, DIRECT METHOD : SPECTROPHOTOM BILIRUBIN, INDIREC METHOD : CALCULATED PAR TOTAL PROTEIN METHOD : SPECTROPHOTOM ALBUMIN METHOD : SPECTROPHOTOM GLOBULIN METHOD : CALCULATED PAR ALBUMIN/GLOBULIN METHOD : CALCULATED PAR ASPARTATE AMINOT (AST/SGOT)	IETRY, JENDRAS CT RAMETER IETRY, COLORII IETRY, BROMOC RAMETER I RATIO RAMETER TRANSFER	SSIK & GROFF - DIAZOTIZA METRIC -BIURET, REAGENT CRESOL GREEN(BCG) - DYE	6.1 BLANK, SE 3.7 LO BINDING 2.4 1.5 15	w	0.0 - 0.9 6.0 - 8.0 3.97 - 4.9 2.0 - 3.5 1.0 - 2.1	-	mg, g/d g/d RAT	/dL L L TO
METHOD : SPECTROPHOTOM BILIRUBIN, DIRECT METHOD : SPECTROPHOTOM BILIRUBIN, INDIREC METHOD : CALCULATED PAR TOTAL PROTEIN METHOD : SPECTROPHOTOM ALBUMIN METHOD : CALCULATED PAR ALBUMIN/GLOBULIN METHOD : CALCULATED PAR ASPARTATE AMINOT (AST/SGOT) METHOD : SPECTROPHOTOM	IETRY, JENDRAS CT RAMETER IETRY, COLORII IETRY, BROMOC RAMETER I RATIO RAMETER IRANSFER/ IETRY, WITHOU	SSIK & GROFF - DIAZOTIZA METRIC -BIURET, REAGENT CRESOL GREEN(BCG) - DYE	6.1 BLANK, SE 3.7 LO BINDING 2.4 1.5 15	w	0.0 - 0.9 6.0 - 8.0 3.97 - 4.9 2.0 - 3.5 1.0 - 2.1	94	mg, g/d g/d RAT	/dL L L TO







PATIENT NAME : SHEETAL SHARAD MARATHE **REF. DOCTOR : SELF** ACCESSION NO : 0002WC050221 AGE/SEX :36 Years Female :25/03/2023 08:44:47 PATIENT ID : SHEEF2209862 DRAWN AWING 1705RIZVI CEDER MALAD E CLIENT PATIENT ID: RECEIVED : 25/03/2023 08:46:36 400097 ABHA NO REPORTED :27/03/2023 11:04:30 : **Test Report Status** Results **Biological Reference Interval** Units **Final** U/L ALANINE AMINOTRANSFERASE (ALT/SGPT) 15 Upto 33 METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION(P5P) - IFCC ALKALINE PHOSPHATASE 74 35 - 104 U/L METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC GAMMA GLUTAMYL TRANSFERASE (GGT) 19 < 40 U/L METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - G-GLUTAMYL-CARBOXY-NITROANILIDE - IFCC < 223 U/L LACTATE DEHYDROGENASE 220 METHOD : SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - UV-IFCC **BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN** 8 6 - 20 mg/dL METHOD : SPECTROPHOTOMETRY, UREASE -COLORIMETRIC **CREATININE, SERUM** CREATININE 0.740.60 - 1.10mg/dL METHOD : SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE KINETIC - RATE BLANKED - IFCC-IDMS STANDARIZED **BUN/CREAT RATIO** 8 - 15 **BUN/CREAT RATIO** 10.81 METHOD : CALCULATED PARAMETER URIC ACID, SERUM 2.4 - 5.7 mg/dL URIC ACID 4.1METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC- URICASE **TOTAL PROTEIN, SERUM** TOTAL PROTEIN 6.1 6.0 - 8.0 g/dL METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -BIURET, REAGENT BLANK, SERUM BLANK ALBUMIN, SERUM 3.7 Low ALBUMIN 3.97 - 4.94 g/dL METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DYE BINDING GLOBULIN GLOBULIN 2.4 2.0 - 3.5 g/dL METHOD : CALCULATED PARAMETER **ELECTROLYTES (NA/K/CL), SERUM** mmol/L SODIUM, SERUM 139 136 - 145 METHOD : ISE INDIRECT POTASSIUM, SERUM 4.40 3.5 - 5.1mmol/L METHOD : ISE INDIRECT CHLORIDE, SERUM 106 98 - 106 mmol/L

8. wada

Dr. Sneha Wadalkar,M.D (Reg.no.MMC2012/06/1868) Junior Biochemist Page 13 Of 22



view Details Vie







REF. DOCTOR : SELF PATIENT NAME : SHEETAL SHARAD MARATHE ACCESSION NO : 0002WC050221 AGE/SEX :36 Years Female :25/03/2023 08:44:47 PATIENT ID : SHEEF2209862 DRAWN AWING 1705RIZVI CEDER MALAD E CLIENT PATIENT ID: RECEIVED : 25/03/2023 08:46:36 400097 REPORTED :27/03/2023 11:04:30 ABHA NO : Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

METHOD : ISE INDIRECT

Interpretation(s)

Sodium	Potassium	Chloride	
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.	
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison' s disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.	
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)	

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in: Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy(adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency

diseases(e.g.galactosemia), Drugs-insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

Diagnosing diabetes.
 Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range. 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

a. A G gives an evaluation of blood glucose levels for the last couple of months.
 a. AG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

8. wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 14 Of 22







PATIENT NAME : SHEETAL SHARAD MARATHE	REF. I	DOCTOR : SELF	
AWING 1705RIZVI CEDER MALAD E 400097	ACCESSION NO : 0002WC05 PATIENT ID : SHEEF22098 CLIENT PATIENT ID: ABHA NO :		
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units	٦

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

2.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin. 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results. 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, (indirect) bilirubin in Viral hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain

and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLODD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to: • Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:

Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma,Waldenstroms disease

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 15 Of 22

View Details







PATIENT NAME : SHEETAL SHARAD MARATHE REF. DOCTOR : SELF ACCESSION NO : 0002WC050221 AGE/SEX :36 Years Female PATIENT ID DRAWN :25/03/2023 08:44:47 : SHEEF2209862 AWING 1705RIZVI CEDER MALAD E CLIENT PATIENT ID: RECEIVED : 25/03/2023 08:46:36 400097 ABHA NO REPORTED :27/03/2023 11:04:30 :

Test Report Status Final Results

Biological Reference Interval Units

CLINICAL PATH - URINALYSIS						
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE						
PHYSICAL EXAMINATION, URINE						
COLOR	YELLOW					
APPEARANCE	SLIGHTLY HAZY					
CHEMICAL EXAMINATION, URINE						
PH	6.0	5.00 - 7.50				
SPECIFIC GRAVITY	1.020	1.010 - 1.030				
PROTEIN	NOT DETECTED	NOT DETECTED				
GLUCOSE	NOT DETECTED	NOT DETECTED				
KETONES	NOT DETECTED	NOT DETECTED				
BLOOD	NOT DETECTED	NOT DETECTED				
BILIRUBIN	NOT DETECTED	NOT DETECTED				
UROBILINOGEN	NOT DETECTED					
NITRITE	NOT DETECTED	NOT DETECTED				
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED				
MICROSCOPIC EXAMINATION, URINE						
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF			
PUS CELL (WBC'S)	1-2	0-5	/HPF			
EPITHELIAL CELLS	8-10	0-5	/HPF			
CASTS	NOT DETECTED					
CRYSTALS	NOT DETECTED					
BACTERIA	NOT DETECTED	NOT DETECTED				
YEAST	NOT DETECTED	NOT DETECTED				
METHOD : URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEG	GRATED AUTOMATED SYSTEM					

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment

8. wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist











PATIENT NAME : SHEETAL SHARAD MARATHE REF. DOCTOR : SELF ACCESSION NO : 0002WC050221 AGE/SEX :36 Years Female PATIENT ID : SHEEF2209862 DRAWN :25/03/2023 08:44:47 AWING 1705RIZVI CEDER MALAD E CLIENT PATIENT ID: RECEIVED : 25/03/2023 08:46:36 400097 ABHA NO REPORTED :27/03/2023 11:04:30 :

Test Repor	t Status	Final	

Results

Biological Reference Interval Units

Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

g.g.wadal

Dr. Sneha Wadalkar,M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 17 Of 22







PATIENT NAME : SHEETAL SHARAD MARATHE	REF. DOCTOR : S	SELF
	ACCESSION NO : 0002WC050221	AGE/SEX : 36 Years Female
	PATIENT ID : SHEEF2209862	DRAWN :25/03/2023 08:44:47
AWING 1705RIZVI CEDER MALAD E 400097	CLIENT PATIENT ID:	RECEIVED : 25/03/2023 08:46:36
	ABHA NO :	REPORTED :27/03/2023 11:04:30
	1	I

Test Report Status <u>Final</u> Results

Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

MICROSCOPIC EXAMINATION, STOOL

SAMPLE NOT RECEIVED

Interpretation(s)

REMARK

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION
Pus cells	Pus in the stool is an indication of infection
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.
Charcot-Leyden crystal	Parasitic diseases.
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.
Frank blood	Bleeding in the rectum or colon.
Occult blood	Occult blood indicates upper GI bleeding.
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.
рН	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.

ADDITIONAL STOOL TESTS :

- Stool Culture:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if 1. treatment for GI infection worked.
- Fecal Calprotectin: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) 2. from Irritable Bowel Syndrome (IBS).

Dr. Ekta Patil, MD (Reg.No. MMC2008/04/1142) Senior Microbiologist



Page 18 Of 22

View Report








REF. DOCTOR : SELF PATIENT NAME : SHEETAL SHARAD MARATHE ACCESSION NO : 0002WC050221 AGE/SEX :36 Years Female PATIENT ID DRAWN :25/03/2023 08:44:47 : SHEEF2209862 AWING 1705RIZVI CEDER MALAD E CLIENT PATIENT ID: RECEIVED : 25/03/2023 08:46:36 400097 ABHA NO REPORTED :27/03/2023 11:04:30 : Results

- **Test Report Status Biological Reference Interval** Units <u>Final</u>
 - Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia. 3. 4. Clostridium Difficile Toxin Assay: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.
 - Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array 5. Test, (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus, parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
 - Rota Virus Immunoassay: This test is recommended in severe gastroenteritis in infants & children associated with watery 6. diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.



Dr. Ekta Patil,MD (Reg.No. MMC2008/04/1142) Senior Microbiologist



Page 19 Of 22





View Report







REF. DOCTOR : SELF PATIENT NAME : SHEETAL SHARAD MARATHE ACCESSION NO : 0002WC050221 AGE/SEX :36 Years Female DRAWN :25/03/2023 08:44:47 PATIENT ID : SHEEF2209862 AWING 1705RIZVI CEDER MALAD E CLIENT PATIENT ID: RECEIVED : 25/03/2023 08:46:36 400097 ABHA NO REPORTED :27/03/2023 11:04:30 : **Test Report Status** Results Biological Reference Interval Units <u>Final</u>

SPECIALISED CHEMISTRY - HORMONE

	SPECIALISED CHEMISTRY - HOR	CMONE			
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE					
THYROID PANEL, SERUM					
Τ3	111.0	Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0	D		
METHOD : COMPETITIVE ELECTROCHEMILUMINESCE	NCE IMMUNOASSAY				
Τ4	7.48	Non-Pregnant Women 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70			
METHOD : COMPETITIVE ELECTROCHEMILUMINESCE	NCE IMMUNOASSAY				
TSH (ULTRASENSITIVE)	2.440	Non Pregnant Women 0.27 - 4.20 Pregnant Women 1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15	µIU/mL		
METHOD : SANDWICH ELECTROCHEMILUMINESCEN	CE IMMUNOASSAY				

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

	Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
--	---------	-----	----------	-----	----------	---------------------

8. wadal

Dr. Sneha Wadalkar,M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 20 Of 22

View Report







MC-2010

PATIENT NAME : SHEETAL SHARAD MARATHE	REF. DOCTOR : SELF			
	ACCESSION NO : 0002WC050221	AGE/SEX : 36 Years Female		
	PATIENT ID : SHEEF2209862	DRAWN :25/03/2023 08:44:47		
AWING 1705RIZVI CEDER MALAD E 400097	CLIENT PATIENT ID:	RECEIVED : 25/03/2023 08:46:36		
400097	ABHA NO :	REPORTED :27/03/2023 11:04:30		
	1	1		

Test Report Status	<u>Final</u>	Results	Biological Reference Interval Units
	<u> </u>		


1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	 (1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3) Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> **End Of Report** Please visit www.srlworld.com for related Test Information for this accession

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist





Page 21 Of 22







PATIENT NAME : SHEETAL SHARAD MARATHE	REF. DOCTOR : SELF			
	ACCESSION NO : 0002WC050221	AGE/SEX : 36 Years Female		
	PATIENT ID : SHEEF2209862	DRAWN :25/03/2023 08:44:47		
AWING 1705RIZVI CEDER MALAD E 400097	CLIENT PATIENT ID:	RECEIVED : 25/03/2023 08:46:36		
400097	ABHA NO :	REPORTED :27/03/2023 11:04:30		
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units		

CONDITIONS OF LABORATORY	TESTING & REPORTING
--------------------------	--------------------------------

 It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
 All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
 Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.

4. A requested test might not be performed if:

- i. Specimen received is insufficient or inappropriate
- ii. Specimen quality is unsatisfactory
- iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

Test results cannot be used for Medico legal purposes.
 In case of queries please call customer care


(91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

S.S. Wadal

Dr. Sneha Wadalkar,M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 22 Of 22





View Repor

